Psychedelic Renaissance

What is the psychedelic renaissance?

The psychedelic renaissance refers to the dramatic revival of interest in psychedelic substances that has been accelerating since approximately 2006, after a ~40 year period of near-total suppression following the criminalization of psychedelics in the late 1960s and 1970s.

Timeline:

First wave (1950s–1960s):

• Thousands of studies on LSD and psilocybin
• Promising results for depression, alcoholism, end-of-life anxiety
• Over 40,000 patients treated
• Cultural explosion: Timothy Leary, Aldous Huxley, counterculture movement

Suppression (1970–2000s):

• Nixon's War on Drugs; psychedelics classified as Schedule I
• Research effectively halted
• Demonization in media and public discourse
• Underground use continued but without scientific framework

Renaissance (2006–present):

• 2006: Johns Hopkins publishes landmark psilocybin study
• 2016: Michael Pollan begins research for How to Change Your Mind
• 2018: FDA grants Breakthrough Therapy designation to psilocybin for depression
• 2020: Oregon legalizes psilocybin therapy; several cities decriminalize
• 2022: Colorado decriminalizes; Australia approves medical use of psilocybin and MDMA
• Ongoing: Hundreds of clinical trials, billions in investment, growing mainstream acceptance

Why it matters for microdosing

The psychedelic renaissance provides the context in which modern microdosing exists:

• Scientific legitimacy — growing research validates the therapeutic potential of psychedelics, lending credibility to microdosing practice
• Policy change — decriminalization and legalization efforts reduce legal risk and increase access
• Quality information — more research means better understanding of mechanisms, risks, and best practices
• Cultural shift — decreasing stigma allows for more open discussion and community building
• Commercial development — investment in psychedelic medicine is driving innovation in dosing, delivery, and therapeutic protocols
• Microdosing as gateway — microdosing has been a significant driver of mainstream interest in psychedelics, and vice versa

What to watch out for

• Hype cycle — not everything claimed during a "renaissance" will prove true; maintain scientific skepticism
• Commercialization — corporate interests may prioritize profit over patient access and equity
• Equity concerns — the communities most harmed by the War on Drugs must be included in the benefits of reform
• Regulation quality — rushed or poorly designed regulations can create problems; thoughtful policy matters
• Backlash risk — irresponsible use or overhyped claims could trigger a second wave of prohibition